Brief profile AXURAŽ
Memantine is the first and only representative of a new class of Alzheimer drugs – a moderate affinity NMDA-receptor antagonist. Memantine has been developed by Merz Pharmaceuticals and was recently approved in Europe and the USA for the treatment of moderate to severe Alzheimer's disease.
Efficacy of Memantine
- Benefit in cognitive and psychomotor functioning
- Benefit in activities of daily living
- Reduction of care dependence
- Excellent tolerability
Memantine produces symptomatic improvements in learning under conditions of tonic NMDA receptor activation in Alzheimer's disease. In contrast to first generation therapies, memantine is likely to show neuroprotective effects at concentrations used in the treatment of Alzheimer's disease and to slow down disease progression.
Dosage of memantine
Morning |
Afternoon |
|
1st week |
½ tablet or 10 drops |
--- |
2nd week |
½ tablet or 10 drops |
½ tablet or 10 drops |
3rd week |
1 tablet or 20 drops |
½ tablet or 10 drops |
From the 4th week on |
1 tablet or 20 drops |
1 tablet or 20 drops |
More information:
Tolerability of memantine
- In studies of memantine, doctors assessed tolerability as good or very good in the vast majority of patients.
- Memantine displays a favorable tolerability profile even in long-term therapy.
- Memantine's metabolism is not influenced by the cytochrome P-450 system. Therefore memantine has a low potential for interactions in these multimorbid patients.
